Britain and America have signed a significant trade agreement that will guarantee no levies on UK medicine shipments being sold in the US market.
The Terms of the Accord
As part of the deal, the UK has agreed to increase spending on pharmaceuticals through the National Health Service (NHS). This move ensures that tariffs on these key products will be held at nothing for a period of 36 months.
This deal comes after recent statements to hike tariffs on patented pharmaceutical products, with potential rates mentioned reaching double the cost.
"This agreement with the UK reinforces the worldwide climate for new treatments and establishes long-overdue balance to transatlantic pharmaceutical trade," a statement noted.
Economic Importance
Drugs are one of the UK's most significant goods shipped to the United States, which is easily the primary destination for large UK drugmakers.
Export figures reveal that in the one-year period leading up to the third quarter, the UK shipped drugs totaling £11.1bn to the US. This amount accounted for a significant portion of total UK exports in that period.
"This deal safeguards employment, stimulates investment and sets the stage for the UK to become a international leader for biotech and pharma," a minister remarked.
Detailed NHS Changes
The deal includes several specific changes from the British government:
- Price Threshold Increase: The UK will raise the cost ceiling at which it considers new therapies to be prohibitively costly by twenty-five percent.
- Higher Drug Budget: There is a aim to increase total NHS spending on treatments from 0.3% of GDP to 0.6% over the following ten-year period.
- Payback Limit: The percentage drug companies must return to the NHS to stay within budget will be capped at fifteen percent. Last year, repayments were more than twenty percent.
Broader Context
The pact follows a long-running dispute between the pharmaceutical industry and the British authorities over drug pricing and NHS adoption.
These tensions were exacerbated by claims that American customers were charged significantly more for the equivalent treatments than patients in the Britain and the EU.
Over the last 18 months, several significant pharmaceutical investments in the UK have been delayed or abandoned, while major investments have been pledged toward projects in the United States.
The Science Minister publicly accepted that the NHS must spend more on medicines, noting that its spending on drugs had declined as a share of its overall budget over the past decade.
